Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters ; volume:15 ; number:1 ; day:18 ; month:5 ; year:2024 ; pages:1-12 ; date:12.2024
Nature Communications ; 15, Heft 1 (18.5.2024), 1-12, 12.2024
- Creator
-
Zaeck, Luca Mirko
Tan, Ngoc H.
Rietdijk, Wim J. R.
Geers, Daryl
Sablerolles, Roos S. G.
Bogers, Susanne
Dijk, Laura L. A. van
Gommers, Lennert
Leeuwen, Leanne P. M. van
Rugebregt, Sharona
Goorhuis, Abraham
Postma, Douwe F.
Visser, Leo G.
Dalm, Virgil A. S. H.
Lafeber, Melvin
Kootstra, Neeltje A.
Huckriede, Anke L. W.
Haagmans, Bart L.
Baarle, Debbie van
Koopmans, Marion P. G.
Kuy, Paul-Hugo Marie van der
GeurtsvanKessel, Corine H.
Vries, Rory D. de
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-48414-x
- URN
-
urn:nbn:de:101:1-2407291151548.961233201568
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zaeck, Luca Mirko
- Tan, Ngoc H.
- Rietdijk, Wim J. R.
- Geers, Daryl
- Sablerolles, Roos S. G.
- Bogers, Susanne
- Dijk, Laura L. A. van
- Gommers, Lennert
- Leeuwen, Leanne P. M. van
- Rugebregt, Sharona
- Goorhuis, Abraham
- Postma, Douwe F.
- Visser, Leo G.
- Dalm, Virgil A. S. H.
- Lafeber, Melvin
- Kootstra, Neeltje A.
- Huckriede, Anke L. W.
- Haagmans, Bart L.
- Baarle, Debbie van
- Koopmans, Marion P. G.
- Kuy, Paul-Hugo Marie van der
- GeurtsvanKessel, Corine H.
- Vries, Rory D. de
- SpringerLink (Online service)
Other Objects (12)
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Bd. 1+BA1
Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine
Kanalisation Kembach Scheueräcker BA1
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Immunogenicity and effectiveness of a bivalent influenza A/H1N2 vaccine strain against seasonal human influenza A viruses in mice
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
Priming
Priming
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Bd. 1+BA1
Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine
Kanalisation Kembach Scheueräcker BA1
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Immunogenicity and effectiveness of a bivalent influenza A/H1N2 vaccine strain against seasonal human influenza A viruses in mice
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
Priming
Priming
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Bd. 1+BA1
Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine
Kanalisation Kembach Scheueräcker BA1
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
Immunogenicity and effectiveness of a bivalent influenza A/H1N2 vaccine strain against seasonal human influenza A viruses in mice
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming
Priming